IP Library › Granted Patent US 11,779,596
Granted Patent B2
US 11,779,596 · App. 17/397,353 · Granted Oct 10, 2023

Intradialytic use of sodium thiosulfate

Inventor: Craig Sherman (Scottsdale, AZ)
Assignee: HOPE MEDICAL ENTERPRISES, INC.
A61K33/04A61M1/1654A61M1/1656
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,596
App. No.
17/397,353
Granted
Oct 10, 2023
Kind
B2
Abstract

Provided herein are methods for maintaining physiological levels of thiosulfate in a subject undergoing hemodialysis. Also provided herein are methods of administering pharmaceutically acceptable sodium thiosulfate to a subject undergoing hemodialysis.

Claims (20)

1. A method for delaying, precluding, and/or reducing the risk of onset or acquisition of: angina, cerebral vasospasm, claudication, critical limb ischemia, peripheral vascular disease, or sickle cell crisis in a subject undergoing dialysis, comprising intradialytically contacting said subject's blood with a dialyzer membrane that is also in contact with a thiosulfate-spiked dialysate, wherein an aqueous solution comprising sodium thiosulfate is added to an unspiked dialysate as the unspiked dialysate flows from a dialysis machine to a dialyzer membrane, wherein said unspiked dialysate comprises a mixture of water, an acid concentrate solution, and a bicarbonate concentrate solution, and wherein said thiosulfate-spiked dialysate has a pH greater than about 7.0, wherein the concentration of thiosulfate in said thiosulfate-spiked dialysate is no more than about 10 micromolar, and further comprising administering to said subject one or more low-molecular weight medications and/or low-molecular weight vitamins.

2. The method of claim 1 , wherein the physiological level of thiosulfate in said subject is no more than about 10 micromolar.

3. The method of claim 1 , wherein the physiological level of thiosulfate in said subject is between about 500 nanomolar and about 5 micromolar.

4. The method of claim 1 , wherein the physiological level of thiosulfate in said subject is about 3 micromolar.

5. The method of claim 1 , wherein the concentration of thiosulfate in said thiosulfate-spiked dialysate is between about 500 nanomolar and about 5 micromolar.

6. The method of claim 1 , wherein the concentration of thiosulfate in said thiosulfate-spiked dialysate is about 3 micromolar.

7. The method of claim 1 , wherein said aqueous solution comprising sodium thiosulfate comprises no more than about 300 mg/L of sodium thiosulfate.

8. The method of claim 1 , wherein said water comprises no more than about 200 mg/L of thiosulfate.

9. The method of claim 1 , wherein said aqueous solution comprising sodium thiosulfate is added to said unspiked dialysate through a valve that is attached to dialysate tubing at a location before said tubing connects to the dialyzer.

10. The method of claim 9 , wherein said unspiked dialysate flows through said dialysate tubing at a rate between about 500 mL/min and about 700 mL/min.

11. The method of claim 9 , wherein said unspiked dialysate flows through said dialysate tubing at a rate of about 600 mL/min.

12. The method of claim 9 , wherein said aqueous solution comprising sodium thiosulfate is added through said valve to said unspiked dialysate at a rate between about 100 mL/hr and about 550 mL/hr.

13. The method of claim 9 , wherein said aqueous solution comprising sodium thiosulfate is added through said valve to said unspiked dialysate at a rate of about 250 mL per hour.

14. The method of claim 1 , wherein the pH of said thiosulfate-spiked dialysate is between about 7.3 and about 7.5.

15. The method of claim 1 , wherein the pH of said thiosulfate-spiked dialysate is about 7.4.

16. The method of claim 1 , wherein said subject is a human with chronic renal failure.

17. The method of claim 1 , wherein said subject is a human with acute renal failure.

18. The method of claim 1 , wherein said subject undergoes dialysis from three to seven times per week.

19. The method of claim 1 , wherein one or more low-molecular weight medications is administered to said subject.

20. The method of claim 1 , wherein one or more low-molecular weight vitamins is administered to said subject.

Continuity (4)
Continuation 16927901 · Jul 13, 2020
Continuation 15914661 · Mar 7, 2018
Provisional Application 62468871 · Mar 8, 2017
Related Publication 20220031735A1 · Feb 3, 2022
Cited By (1)
US 12,370,212